Alpha-hemolysin (Staphylococcus aureus) (Hla)

Alpha-hemolysin (Hla) is a potent pore-forming cytotoxin secreted by Staphylococcus aureus and serves as a major virulence factor in various human infections. It functions by binding to the host cell surface, specifically the metalloproteinase ADAM10, where it oligomerizes into a heptameric prepore that penetrates the lipid bilayer (Source: UniProt P09616). This pore formation leads to the leakage of intracellular contents, subsequent cell lysis, and the induction of pro-inflammatory signaling pathways that contribute to tissue damage in conditions like necrotizing pneumonia and skin infections (Source: PubMed PMID: 24036120). In clinical development, Hla is targeted by neutralizing monoclonal antibodies such as Suvratoxumab and Tosatoxumab, which aim to attenuate bacterial virulence rather than killing the pathogen directly. This anti-virulence strategy is designed to reduce the severity of S. aureus infections and potentially lower the selective pressure for antibiotic resistance (Source: NIH/NCBI PMC5951174). While primarily associated with S. aureus, hemolysins as a class are produced by various bacteria, but the staphylococcal alpha-toxin remains the most prominent target for therapeutic intervention in modern clinical trials.

Other names

Alpha-toxinStaphylococcal alpha-hemolysinHlyAlpha-HL

Neutralizing monoclonal antibodies bind to the toxin, preventing its attachment to host cell receptors (such as ADAM10) and subsequent heptameric pore formation, thereby protecting host tissues from lysis and inflammation.